Influence of lipids metabolism on platelet activation in vivo.
Platelet aggregability and plasma factor VIII-related antigen (F. VIIIR:AG) level in 16 ischemic heart disease (IHD) patients were increased by isometric exercise and these changes were prevented by administration of a lipid lowering agent, simfibrate, a derivative of clofibrate. Serum total cholesterol (TC) level decreased and the high density lipoprotein-cholesterol (HDL-C)/TC ratio increased with the treatment. Another 7 hyperlipidemics were administered with simfibrate. Platelet malondialdehyde (MDA) production decreased with improvement in lipid profile. In an in vitro study, platelet aggregability and the plasma level of von Willebrand factor (vWF) and F.VIIIR:AG of normal citrated blood were increased by passing it through a glass bead column. Combining above results of the three separate studies, it would be suggested that hyperlipidemia might enhance platelet activation in vivo, which occurred through contact of platelets to atherosclerotic rough vessel surface. The anti-platelet effect of simfibrate might be mediated through its effect on arachidonic pathway in platelets.
D000328:Adult; D000368:Aged; D000941:Antigens / Q000032:analysis; D001792:Blood Platelets / Q000378:metabolism / Q000502:physiology*; D003327:Coronary Disease / Q000097:blood; D005169:Factor VIII / Q000032:analysis / Q000276:immunology; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood; D066298:In Vitro Techniques; D007537:Isometric Contraction; D050356:Lipid Metabolism; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008875:Middle Aged; D010974:Platelet Aggregation; D014462:Ultrafiltration; D014841:von Willebrand Factor / Q000032:analysis
D000941:Antigens; D014841:von Willebrand Factor; D008315:Malondialdehyde; D005169:Factor VIII